Effects of adalimumab treatment on miR-141,miR-335-5p and bone metabolism in patients with rheumatoid arthritis
10.13431/j.cnki.immunol.j.20250027
- VernacularTitle:类风湿关节炎患者应用阿达木单抗治疗对miR-141、miR-335-5p和骨代谢的影响
- Author:
Jiao'e SHENG
1
;
Linchong SU
;
Zhenyu GAO
Author Information
1. 121001,锦州医科大学研究生学院;445000 恩施,湖北民族大学附属民大医院风湿免疫科
- Publication Type:Journal Article
- Keywords:
Rheumatoid arthritis;
Adalimumab;
Microribonucleic acid;
Anti-cyclic citrullinated peptide antibody;
Rheumatoid factor;
Bone metabolism
- From:
Immunological Journal
2025;41(3):187-192
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effects of adalimumab treatment on serum micro ribonucleic acid-141(miR-141),micro ribonucleic acid-335-5p(miR-335-5p),and bone metabolism indexes in patients with rheumatoid arthritis(RA),and to provide a basis for the rational development of clinical treatment plans.Methods 82 cases of patients with RA admitted to our hospital from April 2021 to March 2024 were selected as study subjects,and they were divided into the methotrexate group(41 cases)and the adalimumab group(41 cases)by randomized numerical table method.The methotrexate group was treated with methotrexate tablets orally,and the adalimumab group was treated with adalimumab injection subcutaneously on the basis of methotrexate group,and both groups continued the treatment for 3 months.The efficacy after 3 months of treatment,symptom improvement and adverse reactions during the treatment period were counted;enzyme-linked immunosorbent assay detected the levels of inflammatory response,serum ACPA,RF and bone metabolism indexes before and after 3 months of treatment;and fluorescence quantitative PCR assay detected serum miR-141,miR-335-5p before and after 3 months of treatment.Results The total effective rate after 3 months of treatment was higher in the adalimumab group(90.24％)than in the methotrexate group(73.17％)(P＜0.05).Compared with before treatment,the duration of morning stiffness was shorter in both groups after 3 months of treatment,and it was shorter in the adalimumab group than in the methotrexate group(P＜0.05);pressure pain,number of swollen joints,scores of visual analog score(VAS),28 joints disease activity(DAS28),levels of serum interleukin-22(IL-22),interleukin-17(IL-17),C-reactive protein(CRP),tumor necrosis factor α(TNF-α),miR-141,anti-cyclic citrullinated peptide antibody(ACPA),rheumatoid factor(RF)decreased in both groups,and decreased in the adalimumab group compared with the methotrexate group(P＜0.05);levels of serum miR-335-5p,25 hydroxyvitamin D,osteocalcin(BGP),osteocalcin N-terminal intermediate molecular fragment(N-MID),and bone alkaline phosphatase(B-ALP)were elevated in both groups,and increased in the adalimumab group compared with the methotrexate group(P＜0.05).The overall incidence of adverse reactions during treatment was lower in the adalimumab group(7.32％)than in the methotrexate group(24.39％)(P＜0.05).Conclusion Adalimumab could regulate the levels of inflammatory response indicators,serum miR-141,miR-335-5p,ACPA,RF,and bone metabolism indicators in patients with RA,and promote the improvement of symptoms,which in turn contributes to the improvement of therapeutic efficacy and had a high safety profile.
